CSL Behring revenue increased from $7.3 billion in 2019 to $7.9 billion in 2020, a (7.0%) increase.

Annual Revenue ($)

CSL Behring revenue was $7.85 b in FY, 2020 which is a (7.0%) year over year increase from the previous period.

FY, 2018FY, 2019FY, 2020
Revenue$6.83 b$7.34 b$7.85 b

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

CSL Behring revenue breakdown by business segment: 51.1% from Immunoglobulins, 14.3% from Hemophilia, 8.1% from Albumin, 21.6% from Specialty and 4.8% from Other

FY, 2019FY, 2018FY, 2020
Immunoglobulins3.54 b3.15 b4.01 b
Hemophilia1.05 b1.11 b1.12 b
Albumin1.02 b921 m640 m
Specialty1.57 b1.49 b1.7 b
Other158.9 m158 m380.7 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu